Wang P, Zhang J
Int J Mol Sci. 2025; 26(1.
PMID: 39795994
PMC: 11720239.
DOI: 10.3390/ijms26010136.
Epp S, Chuah S, Halasz M
Int J Mol Sci. 2023; 24(23).
PMID: 38069407
PMC: 10707345.
DOI: 10.3390/ijms242317085.
Contadini C, Ferri A, Cirotti C, Stupack D, Barila D
Cancers (Basel). 2023; 15(13).
PMID: 37444381
PMC: 10340071.
DOI: 10.3390/cancers15133271.
Hassan W, Bakry M, Siepmann T, Illigens B
Biomed Res Int. 2020; 2020:7390473.
PMID: 33381579
PMC: 7755470.
DOI: 10.1155/2020/7390473.
Zhang S, Zeng T, Hu B, Zhang Y, Feng K, Chen L
Front Bioeng Biotechnol. 2020; 8:507.
PMID: 32528944
PMC: 7264161.
DOI: 10.3389/fbioe.2020.00507.
Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma.
Charlet J, Tomari A, Dallosso A, Szemes M, Kaselova M, Curry T
Mol Carcinog. 2016; 56(4):1290-1301.
PMID: 27862318
PMC: 5396313.
DOI: 10.1002/mc.22591.
Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
Yagyu S, Iehara T, Tanaka S, Gotoh T, Misawa-Furihata A, Sugimoto T
PLoS One. 2016; 11(8):e0161039.
PMID: 27513929
PMC: 4981470.
DOI: 10.1371/journal.pone.0161039.
Neonatal tumours.
Moore S
Pediatr Surg Int. 2013; 29(12):1217-29.
PMID: 24173815
DOI: 10.1007/s00383-013-3424-3.
Neuroblastoma and MYCN.
Huang M, Weiss W
Cold Spring Harb Perspect Med. 2013; 3(10):a014415.
PMID: 24086065
PMC: 3784814.
DOI: 10.1101/cshperspect.a014415.
Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines.
Duijkers F, de Menezes R, Goossens-Beumer I, Stumpel D, Admiraal P, Pieters R
Cell Oncol (Dordr). 2013; 36(5):351-62.
PMID: 23864224
DOI: 10.1007/s13402-013-0140-x.
Clinical potentials of methylator phenotype in stage 4 high-risk neuroblastoma: an open challenge.
Banelli B, Merlo D, Allemanni G, Forlani A, Romani M
PLoS One. 2013; 8(5):e63253.
PMID: 23717404
PMC: 3661569.
DOI: 10.1371/journal.pone.0063253.
Choroid plexus papillomas: advances in molecular biology and understanding of tumorigenesis.
Safaee M, Oh M, Bloch O, Sun M, Kaur G, Auguste K
Neuro Oncol. 2012; 15(3):255-67.
PMID: 23172371
PMC: 3578480.
DOI: 10.1093/neuonc/nos289.
Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.
Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W
Genome Biol. 2012; 13(10):R95.
PMID: 23034519
PMC: 3491423.
DOI: 10.1186/gb-2012-13-10-r95.
Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma.
Caren H, Djos A, Nethander M, Sjoberg R, Kogner P, Enstrom C
BMC Cancer. 2011; 11:66.
PMID: 21314941
PMC: 3045360.
DOI: 10.1186/1471-2407-11-66.
Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes.
Thorell K, Bergman A, Caren H, Nilsson S, Kogner P, Martinsson T
BMC Med Genomics. 2009; 2:53.
PMID: 19686582
PMC: 2743704.
DOI: 10.1186/1755-8794-2-53.
The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.
Van Roy N, De Preter K, Hoebeeck J, Van Maerken T, Pattyn F, Mestdagh P
Genome Med. 2009; 1(7):74.
PMID: 19638189
PMC: 2717400.
DOI: 10.1186/gm74.
RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker.
Misawa A, Tanaka S, Yagyu S, Tsuchiya K, Iehara T, Sugimoto T
Br J Cancer. 2009; 100(2):399-404.
PMID: 19165202
PMC: 2634715.
DOI: 10.1038/sj.bjc.6604887.
Carbon dioxide does not affect the methylation status of prognostic important oncogenes Rassf1A and DCR2 in neuroblastoma cells.
Reismann M, Lehmann D, Quandte M, Ure B, Gluer S
Pediatr Surg Int. 2008; 24(12):1327-30.
PMID: 19002696
DOI: 10.1007/s00383-008-2274-x.
CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23.
Michels E, Hoebeeck J, De Preter K, Schramm A, Brichard B, De Paepe A
BMC Cancer. 2008; 8:173.
PMID: 18559103
PMC: 2442116.
DOI: 10.1186/1471-2407-8-173.
Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
Lazcoz P, Munoz J, Nistal M, Pestana A, Encio I, Castresana J
BMC Cancer. 2006; 6:254.
PMID: 17064406
PMC: 1634754.
DOI: 10.1186/1471-2407-6-254.